Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

John Yan, Josette Kamel, Amit Verma, Eric J. Feldman, Dennis L Cooper, Lauren Shapiro, Ridhi Gupta, Nishi Shah, Noah Kornblum, David Levitz, R. Alejandro Sica, Kira Gritsman, Aditi Shastri, Ioannis Mantzaris, Mendel Goldfinger, Marina Konopleva

Blood (2024) 144 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2024-212222

Published: 2024

Journal Articles

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

M Bakri Hammami, Jeevan Shivakumar, Nina Samuel, Rajvi Gor, Mendel Goldfinger, Noah Kornblum, Lauren Shapiro, Aditi Shastri, Ridhi Gupta, David Levitz, Marina Konopleva, Eric J. Feldman, Kira Gritsman, R. Alejandro Sica, Ioannis Mantzaris, Amit Verma, Dennis L Cooper, Nishi Shah

Blood (2024) 144 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2024-208770

Published: 2024

Journal Articles

Neurotoxicity of Axicabtagene Ciloleucel in an Ethnically Diverse, Real-World Cohort

Elizabeth Zeldin, Samantha J Cheng, Ryann Quinn, Kith Pradhan, Mendel Goldfinger, Ioannis Mantzaris, Nishi Shah, Aditi Shastri, Noah Kornblum, Dennis L Cooper, Ridhi Gupta, Lauren Shapiro, Kira Gritsman, Ahmed Abbasi, Amit Verma, Ira Braunschweig, Katharine McNeill, Mark Milstein, R. Alejandro Sica

Blood (2024) 144 (Supplement 1): 7201.

https://doi.org/10.1182/blood-2024-201715

Published: 2024

Journal Articles

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Madeline G D'Agostino, B. Hilda Ye, Murali Janakiram, Dennis L Cooper, Ioannis Mantzaris, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Nishi Shah, Amit Verma, Lauren Shapiro, Ridhi Gupta, Yang Shi, Yanhua Wang, Alyssa De Castro, John X Wei, R. Alejandro Sica

Blood (2024) 144 (Supplement 1): 7732.

https://doi.org/10.1182/blood-2024-208561

Published: 2024

Journal Articles

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Blood (2024) 144 (Supplement 1): 7367.

https://doi.org/10.1182/blood-2024-207521

Published: 2024

Journal Articles

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Blood (2024) 144 (Supplement 1): 6418.

https://doi.org/10.1182/blood-2024-210619

Published: 2024

Journal Articles

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6723.

https://doi.org/10.1182/blood-2024-211307

Published: 2024

Journal Articles

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Blood (2024) 144 (Supplement 1): 6175.

https://doi.org/10.1182/blood-2024-208911

Published: 2024

Journal Articles

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood (2024) 144 (Supplement 1): 4265.5.

https://doi.org/10.1182/blood-2024-208998

Published: 2024

Journal Articles

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Blood (2024) 144 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2024-211956

Published: 2024

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Blood (2024) 144 (Supplement 1): 57.

https://doi.org/10.1182/blood-2024-211685

Published: 2024

Journal Articles

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Blood (2024) 144 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2024-206160

Published: 2024

Journal Articles

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Blood (2024) 144 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2024-208199

Published: 2024

Journal Articles

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Sudipta Biswas, Zeinab Albadry M. Zahran, Xiaorong Gu, Lisa Cardone, Akriti G. Jain, Kateryna Fedorov, Ben K. Tomlinson, Mendel Goldfinger, Amit Verma, Yogenthiran Saunthararajah

Blood (2024) 144 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2024-210609

Published: 2024

Journal Articles

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Blood (2024) 144 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2024-201590

Published: 2024

Journal Articles

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

John X Wei, Mendel Goldfinger, Marina Konopleva, Ioannis Mantzaris, Amit Verma, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2024-206488

Published: 2024

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Lemchukwu Amaeshi, Alex Sisto, Lauren Laufer, Kateryna Fedorov, Rosmi Mathew, David Levitz, Ioannis Mantzaris, Noah Kornblum, Mendel Goldfinger, Alejandro Sica, Dennis L Cooper, Marina Y. Konopleva, Bruce Rapkin, Amit Verma, Aditi Shastri, Nishi Shah

Blood (2023) 142 (Supplement 1): 7397.

https://doi.org/10.1182/blood-2023-188024

Published: 2023

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, Annemarie Munoz, Aradhika Dhawan, Nicole Chambers, Karen Fehn, Joel Victor, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Amit Verma, Mimi Kim, Ulrich Steidl, Eric J Feldman, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2023-188176

Published: 2023

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

Neurotoxicity of Axicabtagene Ciloleucel in an Ethnically Diverse, Real-World Cohort

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only